Literature DB >> 27749968

Psychiatric comorbidity and plasma levels of 2-acyl-glycerols in outpatient treatment alcohol users. Analysis of gender differences.

Nuria García Marchena1, Pedro Araos, Francisco Javier Pavón, Guillermo Ponce, María Pedraz, Antonia Serrano, Francisco Arias, Pablo Romero-Sanchiz, Juan Suárez, Antoni Pastor, Rafael De la Torre, Marta Torrens, Gabriel Rubio, Fernando Rodríguez de Fonseca.   

Abstract

Alcohol addiction is associated with high psychiatric comorbidity. Objective stratification of patients is necessary to optimize care and improve prognosis. The present study is designed to gain insights into this challenge by addressing the following objectives: a) to estimate the prevalence of psychiatric comorbidities in a sample of outpatients seeking treatment for alcohol use disorder, b) to describe the existence of gender differences and c) to validate 2-acyl-glycerols as biomarkers of alcohol use disorder and/or psychiatric comorbidity. One hundred and sixty-two patients were recruited and evaluated with the semi-structured interview PRISM. The presence of psychopathology was associated with a greater number of criteria for alcohol abuse and dependence according to DSM-IV-TR. We found gender differences in psychiatric comorbidity, e.g., mood disorder, as well as in comorbid substance use disorders. The prevalence of lifetime psychiatric comorbidity was 68.5%, with mood disorders the most frequent (37%), followed by attention deficit disorder (24.7%) and anxiety disorders (17.9%). Substance-induced disorders were more frequent in mood and psychotic disorders, whereas the primary disorders were more prevalent in patients with comorbid anxiety disorders. We found that 2-acyl-glycerols were significantly decreased in comorbid anxiety disorders in alcohol dependent patients in the last year, which makes them a potential biomarker for this psychopathological condition.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27749968     DOI: 10.20882/adicciones.728

Source DB:  PubMed          Journal:  Adicciones        ISSN: 0214-4840            Impact factor:   2.979


  10 in total

1.  Quantification of 24 circulating endocannabinoids, endocannabinoid-related compounds, and their phospholipid precursors in human plasma by UHPLC-MS/MS.

Authors:  Waldemar Röhrig; Susanne Achenbach; Birgit Deutsch; Monika Pischetsrieder
Journal:  J Lipid Res       Date:  2019-06-24       Impact factor: 5.922

2.  Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder.

Authors:  Nerea Requena-Ocaña; María Flores-Lopez; Esther Papaseit; Nuria García-Marchena; Juan Jesús Ruiz; Jesús Ortega-Pinazo; Antonia Serrano; Francisco Javier Pavón-Morón; Magí Farré; Juan Suarez; Fernando Rodríguez de Fonseca; Pedro Araos
Journal:  Biomedicines       Date:  2022-04-20

3.  Depression and Cognitive Impairment in a Spanish Sample of Psychoactive Substance Users Receiving Mental Health Care.

Authors:  Bárbara Luque; Victoriana García; Carmen Tabernero
Journal:  Healthcare (Basel)       Date:  2022-05-11

4.  Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder.

Authors:  Sandra Torres Galván; María Flores-López; Pablo Romero-Sanchiz; Nerea Requena-Ocaña; Oscar Porras-Perales; Raquel Nogueira-Arjona; Fermín Mayoral; Pedro Araos; Antonia Serrano; Roberto Muga; Francisco Javier Pavón; Nuria García-Marchena; Fernando Rodríguez de Fonseca
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

5.  Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.

Authors:  Rosa Maza-Quiroga; Nuria García-Marchena; Pablo Romero-Sanchiz; Pedro Araos; Vicente Barrios; María Pedraz; Antonia Serrano; Raquel Nogueira-Arjona; Juan Jesus Ruiz; Maribel Soria; Rafael Campos; Julie Ann Chowen; Jesus Argente; Marta Torrens; Meritxell López-Gallardo; Eva María Marco; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  PeerJ       Date:  2017-10-12       Impact factor: 2.984

6.  Dual Depression: A Sex Perspective.

Authors:  Adriana Farré; Judit Tirado-Muñoz; Marta Torrens
Journal:  Addict Disord Their Treat       Date:  2017-08-04

7.  Higher Impulsivity As a Distinctive Trait of Severe Cocaine Addiction among Individuals Treated for Cocaine or Alcohol Use Disorders.

Authors:  Nuria García-Marchena; David Ladrón de Guevara-Miranda; María Pedraz; Pedro Fernando Araos; Gabriel Rubio; Juan Jesús Ruiz; Francisco Javier Pavón; Antonia Serrano; Estela Castilla-Ortega; Luis J Santín; Fernando Rodríguez de Fonseca
Journal:  Front Psychiatry       Date:  2018-02-13       Impact factor: 4.157

8.  Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients.

Authors:  Nuria García-Marchena; Nieves Pizarro; Francisco J Pavón; Miriam Martínez-Huélamo; María Flores-López; Nerea Requena-Ocaña; Pedro Araos; Daniel Silva-Peña; Juan Suárez; Luis J Santín; Rafael de la Torre; Fernando Rodríguez de Fonseca; Antonia Serrano
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

9.  Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder.

Authors:  Nerea Requena-Ocaña; Pedro Araos; María Flores; Nuria García-Marchena; Daniel Silva-Peña; Jesús Aranda; Patricia Rivera; Juan Jesús Ruiz; Antonia Serrano; Francisco Javier Pavón; Juan Suárez; Fernando Rodríguez de Fonseca
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

10.  Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders.

Authors:  Nuria García-Marchena; Daniel Silva-Peña; Ana Isabel Martín-Velasco; María Ángeles Villanúa; Pedro Araos; María Pedraz; Rosa Maza-Quiroga; Pablo Romero-Sanchiz; Gabriel Rubio; Estela Castilla-Ortega; Juan Suárez; Fernando Rodríguez de Fonseca; Antonia Serrano; Francisco Javier Pavón
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.